Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXIT-BT: Tenecteplase and Butyphthalide for Ischemic Stroke (4.5-6h)
NCT05189509Phase 2Completed
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Feb 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of butylphthalide in ischemic stroke, sponsored by General Hospital of the Northern Theater Command. Started Feb 2022; status: completed.
02
Drugs
butylphthalide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05189509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05189509.